Biotech · Private company · Frederick, MD, US
Dynport Vaccine Company, LLC
Track this companyFree. Adds Dynport Vaccine Company, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards10
- Task A: Early Phase Clinical Trial Units (EPCTU)Fiscal year 2026 · $219.1KNIH RePORTER 75N93022D00016-P00004-759302200001-1 · fetched Nov 12, 2026
- Task B1: Phase I Clinical Trial to Evaluate a Therapeutic for Antibiotic Resistant InfectionsFiscal year 2025 · $32KNIH RePORTER 272201500005I-P00011-759302100202-1 · fetched Nov 12, 2026
- Task A: Early Phase Clinical Trial Units (EPCTU)Fiscal year 2025 · $215.6KNIH RePORTER 75N93022D00016-P00003-759302200001-1 · fetched Nov 12, 2026
- EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASESFiscal year 2025 · $10KNIH RePORTER 75N93025D00025-0-9999-1 · fetched Nov 12, 2026
- Task B1: Phase I Clinical Trial to Evaluate a Therapeutic for Carbapenem-resistant Enterbacterales (CRE) InfectionsFiscal year 2024 · $844.7KNIH RePORTER 272201500005I-P00004-759302200057-1 · fetched Nov 12, 2026
- Task B1: Phase I Clinical Trial to Evaluate a Therapeutic for Carbapenem-Resistant Enterbacterales (CRE) Antibiotic-Resistant InfectionsFiscal year 2024 · $11.9KNIH RePORTER 272201500005I-P00004-759302200057-2 · fetched Nov 12, 2026
- Task B1: Phase I Clinical Trial to Evaluate a Therapeutic for Antibiotic Resistant Gram Negative and Positive Bacterial InfectionsFiscal year 2024 · $284.1KNIH RePORTER 272201500005I-P00009-759302100202-1 · fetched Nov 12, 2026
- Task A: Early Phase Clinical Trial Units (EPCTU)Fiscal year 2024 · $212.1KNIH RePORTER 75N93022D00016-P00002-759302200001-1 · fetched Nov 12, 2026
- Task C1: A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of SARS-CoV-2 TherapeuticsFiscal year 2024 · $219.2KNIH RePORTER 75N93022D00016-P00002-759302300001-1 · fetched Nov 12, 2026
- Task C1: A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of SARS-CoV-2 TherapeuticsFiscal year 2024 · $245.5KNIH RePORTER 75N93022D00016-P00002-759302300001-2 · fetched Nov 12, 2026